Mylan Inc. announced the U.S. launch of its Valsartan Tablets USP 40 mg, 80 mg, 160 mg, and 320 mg, which is the generic version of Novartis' Diovan Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of hypertension, to lower blood pressure.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.19 USD | +2.75% |
|
+7.80% | +3.32% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.32% | 13.32B | |
+60.25% | 841B | |
+38.56% | 625B | |
-4.49% | 360B | |
+18.30% | 327B | |
+9.64% | 300B | |
+14.15% | 242B | |
+3.11% | 228B | |
+16.98% | 227B | |
+12.87% | 174B |
- Stock Market
- Equities
- VTRS Stock
- News Viatris Inc.
- Mylan Inc. Announces U.S. Launch of Valsartan Tablets USP 40 Mg, 80 Mg, 160 Mg, and 320 Mg